

Index

Numbers and Symbols

- 2-aminoisobutyric acid and
 - 2-aminopentanoic acid.
 - See norvaline
- β -amyloid peptide, 54, 55–56, 58, 59, 61, 62, 63
- β -site APP cleaving enzyme 1 (BACE1), 70, 71–72, 74, 75, 77, 108, 111, 112, 114, 115, 116
- β -site of APP cleaving enzyme 1 (BACE1), 71–72, 74, 75, 77

A

- Alcohol consumption in AD
 - patients, 245–246
- Aluminum, 76, 87, 88
- Alzheimer, Alois, 4
- Alzheimer's Disease
 - biomarkers, 37, 160
 - biometals, role in AD, 75–76, 86
 - brain energy metabolism, 133–134, 136
 - brain tissue, 37, 39, 41, 43
 - causes, 2, 193
 - clinical trials for, 70
 - communication issues, 210–211
 - complexity of, 2, 7, 8, 38, 124
 - dairy products/probiotics,
 - relationship between
 - (see dairy products and probiotics)
 - decision making, impact on, 246–247
 - defining, 2, 241
 - depression in (see depression, AD)
 - description of, 1
 - diabetes, relationship between
 - (see diabetes)
 - diagnosis, 96, 98, 237
 - diet associated with, 148
 - diseases associated with, 147
 - early-onset versus late-onset, 4–6, 38, 72, 160, 195, 196
 - economic burden of, 124
 - end of life, 214–215
 - environmental factors, 193
 - evaluating, 237, 238, 241, 242
 - exercise, relationship between, 201, 202
 - features of, 41, 108
 - genes associated with, 24, 54, 72–74, 148, 194–195
 - gliosis, 126
 - hypotheses regarding causes, 160
 - inflammation, role of, 54, 74–75, 136–138
 - insulin-based therapy, 7
 - ischemic etiology, 53, 54–55
 - (see also ischemia, brain)
 - late-stage, 40, 160, 194, 201
 - lifestyle choices associated
 - with, 75, 193, 195
 - liquid chromatography-mass spectrometry (LC-MS)
 - studies, 39
 - memory interference, 197–201
 - memory, role of, 196–197
 - metabolism disturbances, 1–2, 6–8, 14
 - metal detection, 96, 98
 - (see also specific metals)

- microbiome, relationship between
(*see* microbiome, human)
- molecular mechanisms of, 38
- neuropsychological testing
(*see* neuropsychology)
- obesity, relationship between (*see* obesity)
- overview, 70, 124, 147, 193, 194
- oxidative damage, 2–3 (*see also*
oxidative stress)
- pathophysiology, 2–3, 69
- periodontal disease,
relationship between
(*see* periodontal disease)
- prevalence, 69, 124, 160, 194, 226
- progression, 1, 2, 40, 46, 54, 56, 75,
76, 77, 96, 124, 134, 136, 150,
166–167, 182, 194
- protein expression, 39, 41–42
- protemic studies of, 37, 38–39, 39–41,
41–42, 43–44, 44–46
- retina and optic nerve degeneration
(*see* retina and optic nerve
degeneration in AD)
- risk factors, 4, 194–195
- self, sense of, 205, 206, 207–208,
208–209, 211–212,
212–213, 213–214
- semantic impairment (*see* semantic
impairments, AD)
- spectrum of, 4
- stages, 194
- symptoms, 206–107,
208–209, 210–211, 241
- synaptic losses, 44
- vascular connections, 130–132,
136–138
- white matter
degeneration (*see* white matter
degeneration)
- Amyloid precursor protein (APP), 3, 4, 7,
9, 45, 55, 56, 58, 59, 70–71,
73–76, 89, 91–92, 98, 108,
110–112, 115–116, 154
- Amyloid- β (A β), 2, 3–4, 6, 38,
55, 56, 85, 90–91, 91–92,
96, 98, 99, 107, 108, 109–110,
150, 154–155
- A β _{11-x}/A β _{pE11-x}, 116
- A β ₄₋₄₂, 113–115
- A β _{5-x}, 115–116
- A β _{pE3-x}, 112–113
- Anosognosia, 205, 209
- Anti-Tau treatment, 1
- Apolipoprotein E (APOE- ϵ 4), 136
- Arg2, 10–11
- Arginase
-polyamine pathway, 9
activation, 4, 10, 12
arginine, relationship between, 10
inhibitor, 13
- Arginine, 9, 10
arginase, relationship
between, 10
bioavailability, 9
deprivation, 4, 11
metabolism, 7, 9, 12
oxidizing, 4
transport, 9
- Astrocytes, 126
- Autophagy gene expression, 61
- ## B
- Biocuration, 23, 25, 28, 32
- Biometals, role in AD, 75–76, 86. *See also*
specific metals
- Blood-brain barrier, 75, 86
- Brain ischemia. *See* ischemia, brain

Branched-chain amino acids (BCAAs), 1,
4, 7, 12–13
Branched-chain aminotransferases
(BCATs), 12

C

Cadmium, 87, 95, 96
Cannabis use and AD, 247–248
Cationic amino acid
transporters (CATs), 10
Cerebral amyloid angiopathy (CAA),
43, 44
Cholinergic system, 228–229, 230, 233
Copper, 76, 86, 88, 89, 91, 93–94
Cytoscape, 26

D

Dairy products and probiotics, 150–151
Damage-associated molecular patterns
(DAMPs), 95–96
DAVID, 26
Dementia, 2
Dendrite arborization, 27
Dendrite morphogenesis, 27
Depression, AD
defining, 224, 225
diagnosis, 224, 242–244
link between, 225–226, 227–230
overview, 224, 233 (*see also*
cholinergic system;
serotonergic system)
symptoms, 224, 227, 242
Diabetes
Alzheimer's Disease, relationship
between, 7–8, 148–149
insulin, relationship to white matter
degeneration, 128, 129,
133–134, 136–138

F

Fenton reaction, 76
Ferroxidase homeostasis, 89
Formalin-fixed paraffin-embedded (FFPE)
tissue, 42

G

G:Profiler, 26
Gene Ontology (GO)
curation, 28
domains, 26
enrichment analysis, 31
improvement of, 26–28, 30–32
maintenance of, 25
overview, 23, 24–26
product annotations, 25–26, 28–29,
29–30, 32–33
structure, 26
Gene Ontology Causal Activity Modeling
(GO-CAM), 29

H

Haber-Weiss reaction, 76
Harre, Ron, 203
Human microbiome. *See* microbiome, human

I

Interactome, 37, 44–46
Iron, 86, 88, 89, 94, 96
Iron dyshomeostasis, 61–62
Ischemia, brain
AD, relationship between, 54, 63,
132–133
amyloid protein, role of, 56, 61
animals, in, 55, 57
humans, in, 57–58

inflammation, role of, 54
 iron, role of, 61
 neuron death, 60–61
 tau protein, role of, 57–58, 60

J

Jackson's Dilemma, 182

K

KEGG, 24, 31

L

Language impairments, AD. *See* semantic impairments, AD
 Lead, 76, 87, 95
 Liquid chromatography-mass spectrometry (LC-MS), 39

M

Magnesium, 94
 Manganese, 86, 88
 Mass spectrometry, 7, 9, 13, 37, 39, 40, 42, 44–45, 109–111, 112, 113, 114, 115, 128
 Mercury, 87, 95
 Metal homeostasis, 86–87, 98–99
 Metal protein attenuating compounds (MPACs), 98
 Metformin, 7–8
 Microbiome, human
 AD, link to, 147
 brain-gut-microbiota axis, 151–153
 dairy products/probiotics (*see* dairy products and probiotics)
 fecal microbial diversity, 151
 Microglia, 126
 MicroRNAs, 23, 29, 30

Mitophagy gene expression, 61
 Murdoch, Iris, 181–182

N

N-648, 248
 N-truncation, 107
 National Institutes of Health, 28
 Neuron projection development, 26–27
 Neuropsychology
 AD testing, 239–240, 242, 243, 244, 247
 collaboration with other AD doctors, 244–245
 defining, 239
 overview, 238–241
 Nitric oxide, 130–131
 Norvaline, 12, 13
 Norvaline, 12, 13
 Nuerom projection arborization, 27

O

Obesity, 149–150
 Oligodendrocytes, 126, 128–129, 133
 Optic nerve degeneration in AD.
 See retina and optic nerve degeneration in AD
 Ornithine decarboxylase (ODC), 11
 Oxidative stress
 Alzheimer's disease, in, 2, 3, 124, 134, 136, 137, 160, 230
 brain's vulnerability to, 8
 causes, 3, 4, 88, 89, 95, 98, 123, 126, 129, 132
 consequences of, 8–9, 133, 136
 excess iron and, 22, 76, 94
 protections from, 9
 susceptibility to, 10
 trace metals, relationship between, 85, 91, 94, 95, 96

P

Parkinson's disease, 88, 147
Periodontal disease, 149
Pick's disease, 43
Presenilin gene, 5, 53, 59, 71, 73, 89,
110–111, 115, 182

R

Reactive oxygen species (ROS), 8
Reactome, 24
Reactome, 24
Retina and optic nerve degeneration in AD
 color vision, 162, 165, 169
 contrast sensitivity, 162
 early changes, *versus* followup, 167, 169
 eye and brain relationship, 161–162
 functional changes, 164–166
 optical coherence tomography, 163
 optical coherence tomography
 angiography, 163–164
 overview, 159–160
 prognostic value of, 169
 structural changes, 166–167
 visual acuity, 162
 visual fields, 163
 visual integration, 163

S

Sabat, Steven, 205
Secernin-1, 43
Secretases, 4, 55, 73, 89, 90
Selenium, 86
Semantic impairments, AD, 206
 causes of impairments, 185–186
 changes, over course of disease, 180–181
 characteristics of deterioration, 183–184
 emotional component, 187

Murdoch, Iris, case of, 181–182
 network, semantic, 186–187
 overview, 179, 180

Serotonergic system, 229–230, 233
Sodium dodecyl sulfate, 94–95
Sulfatides, 128

T

Tau protein, 8, 14, 53
 accumulation of, 149
 aggregation of, 61
 brain ischemia, expression of in, 60
 brain tissue, in, 38
 dysfunction of, 76
 metal binding, 85, 88, 89, 92–95
 pathogenesis of AD, role in, 42,
 43, 44–46, 63
 phosphorylation, 1, 8, 14, 38, 41, 76,
 124, 126, 132, 160
 staining, 56–57, 57–58

U

UniProt Knowledgebase, 28
Urea cycle, 8–10, 12

W

White matter degeneration, 123–124
 causes, 129, 133
 gliosis, 126
 insulin, relationship between, 128, 129,
 133–134, 136–138
 overview, 125
 pathology, 125, 128
 vascular causes, 130–132

Z

Zinc, 76, 86, 88–89, 91, 93, 96